🇺🇸 FDA
Pipeline program

Vedolizumab SC 108 mg

MLN0002SC-3031

Phase 3 small_molecule completed

Quick answer

Vedolizumab SC 108 mg for Crohn's Disease is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Crohn's Disease
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials